HPV Vaccine for HPV Prevention

Phase 2

Waitlist Available

Led By Hsiao-Hui (Sherry) Chow

Research Sponsored by National Cancer Institute (NCI)

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Ability to understand and the willingness to sign a written informed consent document by the legal representative(s) of the participant

Be younger than 18 years old

Must not have

Receiving active treatment for cancer or an autoimmune condition

Previous vaccination against HPV

Timeline

Screening 3 weeks

Treatment Varies

Follow Up between 6 and 24 months after prime dose and prior to the administration of the second dose

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing how well a new HPV vaccine works in preventing HPV infections.

Who is the study for?

This trial is for healthy, medically well boys and girls who can understand and agree to participate. They must not have had an HPV vaccine before, be on immunosuppressive drugs, or have significant health issues like heart or kidney problems. Pregnant individuals or those with a history of allergic reactions to similar vaccines are excluded.

What is being tested?

The study is testing the effectiveness of the nonavalent HPV vaccine given in a different dosing schedule to prevent nine types of HPV in young participants. It also involves laboratory analysis to monitor biomarkers related to the vaccine's effect.

What are the potential side effects?

While specific side effects aren't listed here, common ones for vaccines like this may include pain at injection site, fever, headache, fatigue, muscle or joint pain. Severe allergic reactions are rare but possible.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I (or my legal representative) can understand and am willing to sign the consent form.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I am currently receiving treatment for cancer or an autoimmune disease.

Select...

I have been vaccinated against HPV.

Select...

I have a bleeding disorder that prevents me from getting shots in my muscles.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ between 6 and 24 months after prime dose and prior to the administration of the second dose

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~between 6 and 24 months after prime dose and prior to the administration of the second dose

This trial's timeline: 3 weeks for screening, Varies for treatment, and between 6 and 24 months after prime dose and prior to the administration of the second dose for reporting.